Detalles de la búsqueda
1.
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.
Oncologist;
28(12): 1034-1048, 2023 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37774394
2.
Types of Liquid Biopsies: Understanding the Different Lenses Through Which They Can Detect Cancer.
Oncologist;
28(4): 281-282, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36848223
3.
Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.
Oncologist;
27(5): 336-337, 2022 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403691
4.
Should Vital Signs Be Routinely Obtained Prior to Intravenous Chemotherapy? Results From a 2-Center Study.
Cancer Control;
22(4): 515-9, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26678980
5.
Waldenström macroglobulinemia.
Clin Adv Hematol Oncol;
13(1): 56-66, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25679974
6.
False-Positive Liquid Biopsy Assays Secondary to Overlapping Aberrant Methylation from Non-Cancer Disease States.
Case Rep Oncol;
16(1): 1536-1541, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38058505
7.
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
J Nucl Med Technol;
51(1): 22-25, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36195446
8.
Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies.
Front Oncol;
13: 1305181, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38044994
9.
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes.
JCO Precis Oncol;
7: e2300118, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37769226
10.
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.
Oncogene;
42(44): 3252-3259, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37731056
11.
Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge.
Front Oncol;
12: 847299, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35837097
12.
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
J Clin Oncol;
40(24): 2846-2857, 2022 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35839443
13.
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
J Immunother Cancer;
10(6)2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35710297
14.
Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
J Immunother Cancer;
10(1)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101943
15.
Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte® Platform.
Front Pharmacol;
13: 835727, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35308236
16.
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Nat Commun;
13(1): 7477, 2022 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36463294
17.
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours.
BMJ Open;
12(5): e060342, 2022 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35636789
18.
Deploying an artificial intelligence-based online search tool to increase patients' access to and understanding of solid tumor gastrointestinal clinical trials.
J Gastrointest Oncol;
12(5): 2045-2051, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34790372
19.
BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
BMJ Open;
11(9): e047831, 2021 09 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34561256
20.
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study.
Front Oncol;
11: 736620, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34604072